MEDP Medpace Holdings, Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.…
Industry Peers
Diagnostics & ResearchKey Statistics
About Medpace Holdings (NASDAQ: MEDP)
›
Medpace Holdings (NASDAQ: MEDP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Diagnostics & Research industry, part of the Healthcare sector, and reports about 6,600 employees.
The shares were at 633.98 USD on 19 November 2026, up 7.1% over 52 weeks. Its 52-week range is 373.00 USD to 693.72 USD: the price is 8.6% below the high and 70.0% above the low.
At a market capitalisation of 17.73B USD, it trades at 35.2 times trailing earnings and 31.9 times forward earnings. The median trailing P/E of its 18 largest Diagnostics & Research peers is 35.5, so MEDP is valued in line with them.
Medpace Holdings reports return on equity of 98.3%, an operating margin of 21.4% and revenue up 8.5% year over year.
It holds more cash than debt, a net cash position of 533.86M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 13 analysts cover the stock; their mean price target of 651.31 USD is 2.7% above the current price. The next earnings report is expected on 8 February 2027.